ATM and cancer: Currently, antisense Ataxia-telangiectasia mutated (ATM) and the epidermal growth factor receptor (EGFR) genetic therapy had been explored as the radiosensitization strategy on a human cancer cell line (Fan et al., 2000; Guha et al., 2000; ping et al., 2010).